SEMA7A and adrenal cortex carcinoma: This suggests that SEMA7A protein levels determined by IHC can potentially be used as a biomarker to identify specific subgroups of ACC patients and score tumor aggressiveness instead of or in conjunction with RNA-Seq analyses.